AstraZeneca (AZN)

3,245.50p
   
  • Change Today:
    -5.00p
  • 52 Week High: 3,521.50p
  • 52 Week Low: 2,745.00p
  • Currency: UK Pounds
  • Shares Issued: 1,252.09m
  • Volume: 585,628
  • Market Cap: £40,637m
  • RiskGrade: 76
  • Beta: 0.69

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 5.5% 5.5%
Div Cover 2.3 1.9
Op Mrgn 29.1% 26.4%
ROCE 74.6%  
Latest F'cast
P/E 7.9 9.7
PEG n/a n/a
Pr/Revenue 2.3 2.4
Pr/Book 2.7  
Latest F'cast
Revenue -16.7% -61.3%
PBT -37.6% -62.9%
EPS -12.0% -18.0%
DPS n/a -58.9%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-08 31,601.00 8,681.00 510.00¢ 8.6 0.5 +16% 205.00¢ 4.7%
31-Dec-09 32,804.00 10,807.00 632.00¢ 7.2 0.3 +24% 230.00¢ 5.1%
31-Dec-10 33,269.00 10,977.00 671.00¢ 6.8 1.1 +6% 255.00¢ 5.6%
31-Dec-11 33,591.00 12,367.00 728.00¢ 6.4 0.8 +8% 280.00¢ 6.0%
31-Dec-12 27,973.00 7,718.00 641.00¢ 7.1 n/a -12% 280.00¢ 6.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-13 16,915.26 4,470.92 334.37p 9.7 n/a -18% 179.58p 5.5%
31-Dec-14 16,374.11 4,497.39 319.07p 10.2 n/a -5% 181.57p 5.6%

Copyright © 2013 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Announces top-line results for SAVOR study 19-Jun-2013 07:00 RNS
Director/PDMR Shareholding 12-Jun-2013 15:00 RNS
Director/PDMR Shareholding 12-Jun-2013 15:00 RNS

AstraZeneca ShareCast News

London pre-open: Tentative start expected as mar... 19-Jun-2013 ShareCast
AstraZeneca announces results of SAVOR study 19-Jun-2013 ShareCast
AstraZeneca sets up new headquarters in Cambridge 18-Jun-2013 ShareCast

AstraZeneca Motley Fool Analysis & Commentary

The Stock Picker's Guide to AstraZeneca plc 13-June-2013 Motley Fool
What Are The City's Expectations For AstraZeneca... 12-June-2013 Motley Fool
AstraZeneca plc To Spend Up To $1.15Bn On New Ac... 10-June-2013 Motley Fool

AstraZeneca Top Newspaper Links

New partnership to fight diabetes 18-Jun-2013 Express & Star
AstraZeneca seals deal for lung drug firm 11-Jun-2013 Express & Star
AstraZeneca to buy US respiratory drug specialis... 11-Jun-2013 Guardian

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 3,245.50p
Change Today -5.00p
% Change -0.15 %
52 Week High 3,521.50p
52 Week Low 2,745.00p
Volume 585,628
Shares Issued 1,252.09m
Market Cap £40,637m
Beta 0.69
RiskGrade 76

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
74.31% above the market average74.31% above the market average74.31% above the market average74.31% above the market average74.31% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
31.64% above the market average31.64% above the market average31.64% above the market average31.64% above the market average31.64% above the market average
32.00% above the sector average32.00% above the sector average32.00% above the sector average32.00% above the sector average32.00% above the sector average
Income
93.64% above the market average93.64% above the market average93.64% above the market average93.64% above the market average93.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
94.14% below the market average94.14% below the market average94.14% below the market average94.14% below the market average94.14% below the market average
89.74% below the sector average89.74% below the sector average89.74% below the sector average89.74% below the sector average89.74% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 22
Sell 4
Strong Sell 7
Total 36
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 13-Feb-13 08-Aug-12
Paid 18-Mar-13 10-Sep-12
Amount 190.00¢ 90.00¢

Trades for 19-Jun-2013

Time Volume / Share Price
10:03 155 @ 3,245.50p
10:02 70 @ 3,245.50p
10:01 30 @ 3,245.50p
10:00 480 @ 3,247.00p
10:00 99 @ 3,246.50p

AstraZeneca Key Personnel

CEO Pascal Soriot

Top of Page